Medical Treatments for Prostate CancerThere are many different medical treatments for prostate cancer that involve the clinical care of a healthcare professional. These treatments include expectant therapy, surgery, radiation therapy, hormone therapy, and chemotherapy. Expectant therapy is to carefully observe and monitor the prostate cancer. Because prostate cancer cells often spread very slowly, many older men who have the disease may not need more extensive treatment. However, expectant therapy usually includes routine physician examinations, including digital rectal exams and PSA tests. The different types of surgery for prostate cancer are radical prostatectomy - an open-surgery procedure in which the entire prostate gland and surrounding tissue are removed. Transurethral resection of the prostate (TURP) - surgery to remove part of the prostate gland that surrounds the urethra. Cryosurgery - this procedure involves killing the cancer cells by freezing them with a small metal tool placed in the tumor. Side effects of prostate cancer surgery include incontinence and impotence. Incontinence is the inability to control urine and may result in dribbling of urine, especially immediately after surgery. Normal control usually returns within weeks or months after surgery. Impotence is the inability to achieve an erection. For a month, or so, after surgery, most men are not able to get an erection. Eventually, approximately 40 to 60 percent of men will be able to get an erection sufficient for sexual intercourse, but without ejaculation of semen, since removal of the prostate gland prevents that process.Radiation therapy uses high energy rays to kill or shrink cancer cells, and to decrease their ability to divide. Radiation is often used to treat prostate cancer that is still confined to the prostate gland, or has spread only to nearby tissue. If the disease is advanced, radiation may be used to reduce the size of the tumor and to provide relief from symptoms. Possible side effects of radiation for prostate cancer may include diarrhea, with or without blood in the stool, and colitis, problems associated with urination, a degree of impotence (inability to get an erection), which may occur within two years of radiation therapy. The goal of hormone therapy is to lower the level of male hormones in the body, particularly testosterone. Hormone therapy does not cure the cancer, and is often used to treat persons whose cancer has spread or recurred after treatment. Produced mainly in the testicles, testosterone causes prostate cancer cells to grow. Thus, reduced testosterone levels can make the prostate cancer shrink and become less active. Most studies show that hormone therapy works better if it is started early. Chemotherapy is the use of powerful, anti-cancer medications to kill cancer cells.. Hospitalization may be needed to monitor treatment and chemotherapy's side effects. Common side effects of chemotherapy include: nausea and vomiting, hair loss, anemia, reduced ability of blood to clot, mouth sores, increased likelihood of developing infections, fatigue. Most side effects disappear once treatment is stopped. |
| multidisciplinary prostate cancer symposium |
|
Audio Medica - Medical Audio News Interviews & Podcasts | Audio Reporting from: - 2005 Multidisciplinary Prostate Cancer Symposium, February 17-19, Hyatt Grand Cypress, Orlando, Florida In this edition: Will they or ASCO Prostate Cancer Symposium - ASCO Foundation For the third consecutive year, three leading medical specialty societies will co-sponsor the three-day multidisciplinary 2007 Prostate Cancer Symposium: A Multidisciplinary Prostate Cancer Symposium This activity is not sanctioned by, nor a part of, American Society of the Clinical Oncology (ASCO) Multidisciplinary Prostate Cancer Symposium. Highlights from the 2005 Multidisciplinary Prostate Cancer The following studies were highlighted at the symposium. These studies describe a new type of treatment for metastatic prostate cancer, the use of higher 2nd Annual Multidisciplinary Prostate Cancer Symposium These materials and the related activity are not sanctioned by the 2nd Annual Multidisciplinary Prostate Cancer Symposium or the commercial supporter of the Vitamin D May Lower Prostate Cancer Risk SOURCES: 2005 Multidisciplinary Prostate Cancer Symposium, cosponsored by the American Society of Clinical Oncology, the Prostate Cancer Foundation, American Society of Clinical Oncology 2007 Update of Purpose: To update the recommendations for the use of tumor marker tests in the prevention, screening, treatment, and surveillance of breast cancer. Prostate Cancer Symposium - ASCO The Prostate Cancer Symposium Awards $25000 to Oncology Fellows today at a press conference at the 2005 Multidisciplinary Prostate Cancer Symposium, Multidisciplinary Prostate Cancer Symposium - Prostate Cancer In February 2006, nearly 1500 practicing physicians, biopharmaceutical executives and government policy makers joined the PCF, the American Society of Multidisciplinary Oncology Meetings Expanding on the Prostate Cancer Symposium, this new symposium offers The Multidisciplinary Head and Neck Cancer Symposium held January 18-20, 2007, |
| multidisciplinary prostate cancer symposium |
|
lateral lobes of prostate male prostate milking prostate cancer gleason score treatment lower back pain prostate |